PR
PROK.US ProKidney Corp.
- Market cap
- USD 427M
- P/E
- -
- P/B
- 97.15x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PROK.US undervalued?
Graham numberThe Graham number of ProKidney Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ProKidney Corp. fundamental analysis
No fundamental analysis for ProKidney Corp. yet.
ProKidney Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-0…
Full company profileProKidney Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ProKidney Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 76.0K | 893K | 733K |
| Gross Profit | - | - | -1.98M | -3.04M | -3.17M | 76.0K | 893K | -131M |
| Operating Income | -79.4M | -27.0M | -55.1M | -153M | -152M | -184M | -165M | -196M |
| EBITDA | -18.3M | -26.1M | -53.1M | -144M | -126M | -158M | -145M | -182M |
| Net Income | -79.6M | -26.7M | -55.1M | -108M | -35.5M | -61.2M | -69.0M | -112M |
| EPS | -1.01 | -0.14 | -1.73 | -1.76 | -0.57 | -0.62 | -0.52 | -0.54 |
| Balance Sheet | ||||||||
| Total Assets | 19.6M | 16.7M | 40.3M | 518M | 421M | 441M | 336M | 210M |
| Total Liabilities | 3.72M | 6.84M | 13.4M | 13.1M | 29.2M | 39.4M | 34.8M | 33.3M |
| Shareholders' Equity | 15.9M | 9.86M | 26.9M | -1.10B | -1.10B | -995M | -1.01B | -907M |
| Cash & Short-term Investments | 15.2M | 4.58M | 20.6M | 490M | 363M | 358M | 270M | 142M |
| Total Debt | 1.11M | 1.56M | 1.33M | 2.40M | 4.41M | 3.24M | 4.04M | 4.34M |
| Cash Flow | ||||||||
| Operating Cash Flow | -76.8K | -25.2M | -50.3M | -77.1M | -90.1M | -126M | -120M | -161M |
| Capital Expenditure | 1.31K | 5.46M | 5.19M | 1.85M | 34.2M | 29.5M | 15.2M | 11.8M |
| Free Cash Flow | -78.1K | -30.6M | -55.5M | -78.9M | -124M | -156M | -135M | -173M |
| Ratios | ||||||||
| ROE | -501.3% | -271.2% | -204.9% | - | - | - | - | - |
| ROA | -406.1% | -160.2% | -136.8% | -20.9% | -8.4% | -13.9% | -20.6% | -53.3% |
| Net Profit Margin | - | - | - | - | - | -80,507.9% | -7,725.2% | -15,282.0% |
| Debt to Equity | 0.07x | 0.16x | 0.05x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ProKidney Corp. dividends
ProKidney Corp. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:1 on Jul 12, 2022.
Who owns ProKidney Corp.
- Insiders 46.30%
- Institutions 29.42%
- Public & others 24.29%
- Shares outstanding 209M
- Free float 185M
Top funds holding PROK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NUMC B0-B | 3.43M | 1.64% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.60M | 1.24% | 0.00% | Oct 2026 |
| Morgan Stanley Insight I | 1.12M | 0.54% | 0.00% | Jun 2026 |
| BrighthouseI Morgan Stanley Discovery B | 1.08M | 0.52% | 0.00% | Sep 2026 |
| GBM104 A | 1.00M | 0.48% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 840K | 0.40% | +0.24% | Oct 2026 |
| Fidelity Small Cap Index | 822K | 0.39% | 0.00% | Aug 2026 |
| Morgan Stanley Inst Discovery I | 821K | 0.39% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 762K | 0.36% | +94.14% | Sep 2026 |
| GBM103 A | 750K | 0.36% | 0.00% | Sep 2026 |
| GBM102 A | 700K | 0.34% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 689K | 0.33% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 639K | 0.31% | +47.79% | Sep 2026 |
| MS INVF Global Insight Z | 606K | 0.29% | 0.00% | Jun 2026 |
| Simplify Propel Opportunities ETF | 484K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 437K | 0.21% | +127.93% | Sep 2026 |
| iShares Micro-Cap ETF | 336K | 0.16% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 305K | 0.15% | 0.00% | Oct 2026 |
| Morgan Stanley Inst Inception I | 292K | 0.14% | 0.00% | Jun 2026 |
| Fidelity Series Total Market Index | 276K | 0.13% | +74.71% | Sep 2026 |
Top institutions holding PROK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12.3M | 5.91% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 9.85M | 4.72% | +10.03% | Jun 2026 |
| BlackRock Inc | 5.20M | 2.49% | +274.68% | Jun 2026 |
| Geode Capital Management, LLC | 2.39M | 1.14% | +94.26% | Jun 2026 |
| Bleichroeder LP | 2.00M | 0.96% | 0.00% | Jun 2026 |
| Hennion & Walsh Asset Management Inc | 1.85M | 0.88% | +14.65% | Jun 2026 |
| Artia Global Partners LP | 1.81M | 0.86% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.18M | 0.56% | +2.47% | Jun 2026 |
| Millennium Management LLC | 1.05M | 0.50% | -53.57% | Jun 2026 |
| State Street Corp | 1.05M | 0.50% | +87.83% | Jun 2026 |
| Charles Schwab Investment Management Inc | 782K | 0.37% | +24.52% | Jun 2026 |
| UBS Group AG | 671K | 0.32% | +100.70% | Jun 2026 |
| Northern Trust Corp | 665K | 0.32% | +175.20% | Jun 2026 |
| MYDA Advisors LLC | 641K | 0.31% | +49.44% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 632K | 0.30% | +17.42% | Jun 2026 |
| Bank of America Corp | 545K | 0.26% | -27.64% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 517K | 0.25% | 0.00% | Jun 2026 |
| Simplify Asset Management Inc. | 484K | 0.23% | 0.00% | Sep 2026 |
| Voleon Capital Management LP | 473K | 0.23% | +360.87% | Jun 2026 |
| Amundi | 304K | 0.15% | +4.27% | Jun 2026 |
ProKidney Corp. company profile
- Company name
- ProKidney Corp.
- Ticker
- PROK.US
- Exchange
- USA Stocks
- Listed since
- Jul 12, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 231
- Fiscal year end
- December
- Address
- 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103
- Phone
- 336 999 7019
- Website
- prokidney.com
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. management
10- Dr. Bruce Culleton M.D.CEO & Director · born 1969
- Mr. James Coulston CPAChief Financial Officer · born 1977
- Mr. Todd C. Girolamo Esq., J.D., M.B.A.Chief Legal Officer & Secretary · born 1965
- Mr. Kenneth LockeChief Technical Officer
- Mr. Richard WilliamsChief Information Officer
- Ms. Carla PoulsonChief People Officer
- Dr. Joseph M. Stavas M.D., M.P.H.Senior Vice President of Interventional Procedures
- Dr. Darin J. Weber Ph.D.Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access · born 1968
- Dr. Emily Butler Ph.D.Senior VP of Biometric
- Mr. Gregory P. MadisonChief Commercial Officer · born 1967